KemPharm (NASDAQ:KMPH) had its price target lowered by research analysts at Oppenheimer from $8.00 to $3.00 in a note issued to investors on Thursday, The Fly reports. The firm currently has an “outperform” rating on the specialty pharmaceutical company’s stock. Oppenheimer’s price target would suggest a potential upside of 77.51% from the company’s previous close.
Separately, ValuEngine cut shares of KemPharm from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $6.33.
Shares of KemPharm stock opened at $1.69 on Thursday. KemPharm has a 52-week low of $1.15 and a 52-week high of $7.15. The firm has a market capitalization of $48.20 million, a PE ratio of -0.68 and a beta of 1.63.
Institutional investors and hedge funds have recently made changes to their positions in the business. Janney Montgomery Scott LLC purchased a new stake in KemPharm during the 4th quarter valued at $44,000. Change Path LLC purchased a new stake in KemPharm during the 4th quarter valued at $67,000. Wedbush Securities Inc. purchased a new stake in KemPharm during the 1st quarter valued at $72,000. Northern Trust Corp boosted its position in KemPharm by 34.0% during the 4th quarter. Northern Trust Corp now owns 43,445 shares of the specialty pharmaceutical company’s stock valued at $78,000 after buying an additional 11,014 shares during the period. Finally, BlackRock Inc. boosted its position in KemPharm by 25.0% during the 4th quarter. BlackRock Inc. now owns 90,426 shares of the specialty pharmaceutical company’s stock valued at $161,000 after buying an additional 18,079 shares during the period. 33.59% of the stock is owned by institutional investors and hedge funds.
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder.
Recommended Story: What is the S&P 500 Index?
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.